Published Date: 31-May-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Antibody Drug Conjugates Market size is expected to reach $13.8 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.
The Breast Cancer segment acquired maximum revenue share in the Global Antibody Drug Conjugates Market by Application in 2021, thereby, achieving a market value of $5.3 billion by 2028. This is due to the relatively high frequency of the disease worldwide, breast cancer accounted for the greatest revenue share in 2021. For instance, as per the World Health Organization, 2.30 million new instances of breast cancer will be identified worldwide in 2020, with 685,000 cancer-related deaths expected. For instance, Enhertu from AstraZeneca, Trodelvy from Gilead Sciences, Inc., and Kadcyla from F. Hoffmann-La Roche Ltd. are three antibody-drug conjugate medicines available for the treatment of breast cancer. The market is likely to develop when these drugs are made available through the patient assistance program. As another example, Kadcyla provides financial help to qualifying patients who are covered by both public and private insurance.
The Non-Cleavable Linker segment is showcasing a CAGR of 14.6% during (2022 - 2028). This is due to the increased use of Kadcyla, which includes a non-cleavable linker. The use of a non-cleavable linker in the synthesis of ADCs that rely on lysosomal breakdown reduces the complete cytotoxicity of the ADC to surrounding healthy cells by preventing non-specific drug release. It is expected to drive the segement. Only FDA-approved ADCs like Kadcyla and Blenrep now use non-cleavable linkers to connect the antibody to the cytotoxic chemical.
The North America market dominated the Global Antibody Drug Conjugates Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.3 billion by 2028. The Europe market is estimated to grow at a CAGR of 13.8% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 15% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/antibody-drug-conjugates-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Unique Offerings from KBV Research
North America Antibody Drug Conjugates Market Future Scope & Opportunities 2022-2028
Europe Antibody Drug Conjugates Market Size & Growth Forecast 2022-2028
Asia Pacific Antibody Drug Conjugates Market Size, Share & Industry Outlook to 2028
LAMEA Antibody Drug Conjugates Market Growth, Trends & Forecasts 2022-2028